Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 28;62(1):25-33.
doi: 10.3325/cmj.2021.62.25.

Non-alcoholic fatty liver disease - a procoagulant condition?

Lucija Virović-Jukić  1 , Sanja Stojsavljević-Shapeski, Jelena Forgač, Michal Kukla, Ivana Mikolašević
Affiliations
Review

Non-alcoholic fatty liver disease - a procoagulant condition?

Lucija Virović-Jukić et al. Croat Med J. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with a number of extrahepatic comorbidities and considerable cardiovascular morbidity and mortality, which is possibly related to coagulation changes associated with metabolic syndrome. Coagulation disorders are common in patients with liver disease of any etiology, and here we review possible alterations in coagulation cascade specific to NAFLD. We discuss derangements in the coagulation cascade and fibrinolysis, endothelial dysfunction, and platelet abnormalities as possible culprits for altered coagulation and explore the significance of these changes for potential treatment targets.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Changes in coagulation factors, platelet activity, fibrin clot properties, and endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD) leading to a procoagulant state. Abbreviations: IL – interleukin; NO – nitric oxide; PAI – plasminogen activator inhibitor; ROS – reactive oxygen species; tPA – tissue plasminogen activator; TNF – tumor necrosis factor; vWF – von Willebrand factor.
See this image and copyright information in PMC

References

    1. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol. 2014;20:13306–24. doi: 10.3748/wjg.v20.i37.13306. - DOI - PMC - PubMed
    1. Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin Gastroenterol Hepatol. 2013;11:1064–74. doi: 10.1016/j.cgh.2013.02.026. - DOI - PubMed
    1. Yates SG, Gavva C, Agrawal D, Sarode R. How do we transfuse blood components in cirrhotic patients undergoing gastrointestinal procedures? . Transfusion. 2016;56:791–8. doi: 10.1111/trf.13495. - DOI - PubMed
    1. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost. 2009;35:277–87. doi: 10.1055/s-0029-1222606. - DOI - PubMed
    1. Northup PG, Sundaram V, Fallon MB, Reddy KR, Balogun RA, Sanyal AJ, et al. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost. 2008;6:2–9. - PubMed